We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-4.45%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.08B
AUM Growth
+$322M
Cap. Flow
+$648M
Cap. Flow %
21%
Top 10 Hldgs %
37.4%
Holding
321
New
89
Increased
78
Reduced
45
Closed
96

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32M
2
CCCC icon
C4 Therapeutics
CCCC
+$14.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.1M
4
AMRS
Amyris Inc.
AMRS
+$11M
5
TECH icon
Bio-Techne
TECH
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$14.1M
2
DXCM icon
DexCom
DXCM
+$14.1M
3
ICUI icon
ICU Medical
ICUI
+$14M
4
LIVN icon
LivaNova
LIVN
+$12.2M
5
OLPX
Olaplex Holdings
OLPX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 24.06%
2 Materials 0.35%
3 Industrials 0.17%
4 Consumer Discretionary 0.07%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
201
PUT
Cullinan Oncology
CGEM
$1.26B
$481K 0.02%
+45,900
New +$620K
XENE icon
202
Xenon Pharmaceuticals
XENE
$6.31B
$459K 0.01%
15,002
-33,500
-69% -$1M
PYXS icon
203
Pyxis Oncology
PYXS
$201M
$458K 0.01%
113,362
+600
+0.5% +$4.39K
VINC
204
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$434K 0.01%
5,423
+15
+0.3% +$1.85K
SLGCW
205
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$413K 0.01%
204,401
– –
RLMD icon
206
Relmada Therapeutics
RLMD
$503M
$402K 0.01%
14,885
+100
+0.7% +$2.07K
ELVN icon
207
Enliven Therapeutics
ELVN
$4.24B
$370K 0.01%
49,159
+275
+0.6% +$1.81K
PRQR icon
208
CALL
ProQR Therapeutics
PRQR
$262M
$252K 0.01%
+277,900
New +$931K
CSII
209
DELISTED
Cardiovascular Systems, Inc.
CSII
$247K 0.01%
+10,911
New +$212K
BGMS
210
Bio Green Med Solution Inc
BGMS
$5.1M
$237K 0.01%
22
-6
-21% -$72.8K
TCACU
211
DELISTED
Tuatara Capital Acquisition Corporation Unit
TCACU
$198K 0.01%
20,000
– –
ROIVW
212
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$176K 0.01%
199,648
– –
ACHV icon
213
Achieve Life Sciences
ACHV
$687M
$131K ﹤0.01%
17,325
+1,000
+6% +$7.45K
AMLX icon
214
Amylyx Pharmaceuticals
AMLX
$2.6B
$129K ﹤0.01%
+10,000
New +$226K
SVRA icon
215
Savara
SVRA
$1.17B
$124K ﹤0.01%
95,014
+600
+0.6% +$723
MTCR
216
DELISTED
Metacrine, Inc. Common Stock
MTCR
$121K ﹤0.01%
198,230
+1,100
+0.6% +$577
MAPSW
217
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$110K ﹤0.01%
50,000
– –
TALKW
218
DELISTED
Talkspace Inc Warrant
TALKW
$103K ﹤0.01%
427,194
– –
CBIO
219
Crescent Biopharma
CBIO
$610M
$100K ﹤0.01%
+877
New +$103K
WVE icon
220
Wave Life Sciences
WVE
$1.03B
$82K ﹤0.01%
40,886
-153,220
-79% -$375K
RCOR.WS
221
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$41K ﹤0.01%
150,632
– –
EFTRW
222
DELISTED
eFFECTOR Therapeutics, Inc. Warrant
EFTRW
$35K ﹤0.01%
100,541
– –
ACAD icon
223
Acadia Pharmaceuticals
ACAD
$5.07B
– –
-50,000
Closed -$1.21M
ACIU icon
224
AC Immune
ACIU
$267M
– –
-33,997
Closed -$168K
ACRS icon
225
Aclaris Therapeutics
ACRS
$860M
– –
-48,266
Closed -$702K
7 8
9
10 11

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Pura Vida Investments held 321 positions worth $3.08B, up 12% from $2.76B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $648M of net new capital in Q1 2022, opening 89 new positions and adding to 78 existing holdings. Its largest new stake was Biogen: 147,135 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 30% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was ICU Medical, an estimated $14M trimmed.

  • Pura Vida Investments's largest Q1 2022 buy was Biogen: 147,135 shares worth $31M.
  • Pura Vida Investments added most to C4 Therapeutics in Q1 2022, an estimated $14.5M increase.
  • Pura Vida Investments's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $14M.
  • Pura Vida Investments fully exited Natera in Q1 2022, selling an estimated $14.1M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $3.08B portfolio in Q1 2022.
  • Pura Vida Investments opened 89 new positions and closed 96 in Q1 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $3.08B.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.